An announcement from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) is now available.
Lumos Diagnostics Holdings Limited reported a significant increase in revenues by 128% to $6.3 million for the half-year ending December 31, 2024, while reducing its loss by 56.3% to $2.8 million compared to the previous period. Despite the improved financial performance, the company did not declare any dividends and highlighted a material uncertainty regarding its ability to continue as a going concern, which may affect stakeholders’ confidence.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Limited operates in the diagnostics industry, focusing on the development and commercialization of rapid point-of-care diagnostic tests. The company aims to provide innovative diagnostic solutions to improve patient care and healthcare outcomes.
YTD Price Performance: -27.50%
Average Trading Volume: 1,842,615
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$21.71M
See more insights into LDX stock on TipRanks’ Stock Analysis page.